PRIMARY STUDY
Renovascular protective effects of erythropoietin in patients with chronic kidney disease
Key Findings: Treatment with erythropoietin (EPO) in patients with chronic kidney disease (CKD) significantly improved serum hemoglobin levels, and decreased inflammatory biomarks including urinary protein, L-FABP and 8-OHdG, carotid IMT, baPWV, plasma BNP and serum ADMA.
Type of Study: Clinical Trial
Study Sample Size: 15
Study Result: Positive
Research Location(s): Japan
Year of Pub: 2011
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Route of Administration: Endogenous
Citation: Fujiwara N, et al. Renovascular protective effects of erythropoietin in patients with chronic kidney disease. Intern Med. 2011; 50:1929-34. doi: 10.2169/internalmedicine.50.5145
Authors: Fujiwara N, Nakamura T, Sato E, Kawagoe Y, Hikichi Y, Ueda Y, Node K
